Nucleic acid testing (NAT) is the method of choice for detection and quantification of a wide range of micro organisms. Primerdesign manufactures and supplies high quality quantitative real-time PCR kits for the detection and simultaneous quantification of numerous significant pathogens . A copy number standard curve is provided for quantification and an the internal extraction template (DNA or RNA), controls for the quality of the nucleic acid extraction and eliminates false negative results.
The kit is designed with the broadest possible detection profile to ensure that all clinically relevant strains and subtypes are detected. Target sequences are selected by working with data from key opinion leaders in the field. Multiple sequence alignments and unprecedented real-time PCR expertise in design and validation ensure the best possible kit.
Details of the target and priming specificity are included in the individual handbooks above.
Packaged, optimised and ready to use. Expect Better Data.
Exceptional value for money
Rapid detection of all clinically relevant subtypes
Positive copy number standard curve for quantification
Highly specific detection profile
High priming efficiency
Broad dynamic detection range (>6 logs)
Sensitive to < 100 copies of target
Accurate controls to confirm findings
A rapid, high performance dye-terminator removal process based on the paramagnetic bead technology. The paramagnetic bead format requires no centrifugation or filtration and is easily performedmanually or fully automated for high throughput dye-terminator removal. Compared to similar systems, this product produces sequences with longer Phred 20 read lengths and higher signal intensities than any other purification technology.
Specifications
| Features | Specifications |
| Main Functions | Removal of free fluorescent dye from sequencingsolution (Replace Beckmen or agencourt CleanSeq) |
| Applications | Automated sequences |
| Purification technology | Magnetic beads technology |
| Process method | Manual or automatic |
| Sample type | DNA doped with fluorescentdye |
| Sample amount | 5μl |
| Recovery | 90% |
| Elution volume | ≥25μl |
| Operation time | ≤50 minutes |
The CleanSeq method contains magnetic particles in an optimized binding buffer to selectively capture sequencing extension products. The protocol can be performed directly in the thermal cycling plate. Unincorporated dyes, nucleotides, salts and contaminants are removed using a simple washing procedure. The purification procedure is amenable to a variety of automation platforms since it requires no centrifugation or vacuum filtration.
Advantages
Kit Contents
| Contents | BCS-5 | BCS-50 | BCS-500 |
| CleanSeq Beads | 5 ml | 50 ml | 500 ml |
Storage and Stability
CleanSeq Beads should be stored at 2-8°C upon arrival and is stable up to 6 months under the condition. However, short-term storage (up to 12 weeks) at room temperature (15-25°C) does not affect its performance. Mix CleanSeq Beads well before using. The reagent should appear homogenous and consistent in color.
DO NOT FREEZE.
A rapid, high performance dye-terminator removal process based on the paramagnetic bead technology. The paramagnetic bead format requires no centrifugation or filtration and is easily performedmanually or fully automated for high throughput dye-terminator removal. Compared to similar systems, this product produces sequences with longer Phred 20 read lengths and higher signal intensities than any other purification technology.
| Clone | IHC512 |
| Source | Mouse Monoclonal |
| Positive Control | Hairy Cell Leukemia |
| Dilution Range | 1:200 |
Annexin A1 (ANXA1) is a membrane protein that plays a role in innate and adaptive immunity by controlling the biosynthesis of inflammation, prostaglandins, and leukotriene mediators. This target is overexpressed in 97% of all samples from patients with with hairy cell leukemia, and is absent in other B-cell lymphomas. High ANXA1 expression is frequently associated with advanced stage esophageal and esophagogastric junction adenocarcinoma, and is also linked to advanced and metastatic disease states.